SCHEMBL4299811

SCHEMBL4299811

Nc1nc2cccnc2c2c1ncn2N

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TLR7 Q9NYK1 5/20 0.42
LMNA P02545 3/20 0.42
POLB P06746 1/20 0.42
HRH2 P25021 1/20 0.42
ADRA1D P25100 1/20 0.42
HTR2A P28223 1/20 0.42
ADORA2A P29274 1/20 0.42
ADRA1A P35348 1/20 0.42
NUDT1 P36639 1/20 0.42
HTR2B P41595 1/20 0.42
PDE4D Q08499 1/20 0.42
KCNH2 Q12809 1/20 0.42
PRMT5 O14744 1/20 0.41
HRH4 Q9H3N8 1/20 0.38
DHFR P00374 1/20 0.36
TLR8 Q9NR97 4/20 0.35
KDM4E B2RXH2 2/20 0.35
MAPT P10636 2/20 0.35
ALDH1A1 P00352 2/20 0.35
GAA P10253 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4753594 0.79 TLR7 (0.59) TLR7LMNAPOLBHRH2ADRA1D
SCHEMBL18587110 0.78 TLR7 (0.46) TLR7LMNAPOLBHRH2ADRA1D
SCHEMBL4301037 0.76 DHFR (0.41) TLR7LMNAPOLBHRH2ADRA1D
Epetirimod SCHEMBL29350668 0.76 TLR7 (0.70) TLR7LMNAPOLBHRH2ADRA1D
Epetirimod SCHEMBL544542 0.76 TLR7 (0.70) TLR7LMNAPOLBHRH2ADRA1D
Epetirimod SCHEMBL29454521 0.76 TLR7 (0.70) TLR7LMNAPOLBHRH2ADRA1D
SCHEMBL3358559 0.75 TLR7 (0.43) TLR7LMNAPOLBHRH2ADRA1D
SCHEMBL544917 0.74 CCR1 (0.39) LMNAHTR2AADRA1AHTR2BPRMT5
SCHEMBL4758357 0.74 TLR7 (0.40) TLR7LMNAPOLBHRH2ADRA1D
SCHEMBL5505834 0.74 TLR7 (0.38) TLR7LMNAPOLBHRH2ADRA1D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090270443-A1 1-AMINO IMIDAZO-CONTAINING COMPOUNDS AND METHODS COLEY PHARMACEUTICAL GROUP, INC. 2009-10-29 US disclosed
WO-2006026760-A2 1-AMINO IMIDAZO-CONTAINING COMPOUNDS AND METHODS 3M INNOVATIVE PROPERTIES COMPANY (US) 2006-03-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270443-A1 1-AMINO IMIDAZO-CONTAINING COMPOUNDS AND METHODS IL2, IL4I1, IFNG TLR7 188/4885LMNA 3812/4885POLB 1638/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.